Analysis

Key stats

About Putnam BioRevolution ETF

SYNB holds a high conviction portfolio that provides exposure to bio revolution, which involves technological advancements in the biological and life sciences that contribute to transforming the economy. The fund primarily invests in (i) technology enablers that provide the materials, equipment, and knowledge to enable biological production, (ii) disruptive biotech or synthetic bio companies, and (iii) other firms positioned to benefit from the theme. The funds exposure goes beyond healthcare, as it may also invest in other sectors that are likely to be positively impacted, such as consumer discretionary, consumer staples, materials, and agriculture. SYNB's portfolio typically comprises growth stocks. In selecting stocks, the fund manager considers valuation, financial strength, growth potential, industry position, projected future earnings, cash flows, and dividends.